Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan.
Authors of this article are:
Benitez J Cool CL Scotti DJ.
A summary of the article is shown below:
AIM: To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU).PATIENTS & METHODS: Administrative claims data were analyzed from health plan members whose treatment was guided by GeneSight® Psychotropic testing (CPGx® cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods.RESULTS: 205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings.CONCLUSION: Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as: CPGx®;anxiety;bipolar disorder;combinatorial pharmacogenomics;depression;economic utility;managed care;pharmacogenomics;pharmacogenomics testing;psychiatry.
Categories: Science News